The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bio Pharma Buffer Market Research Report 2025
Synopsis
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Most purification steps for downstream processing of biologics require buffers to equilibrate, condition, wash, elute, or concentrate the product. They are used in product isolation and purification steps to facilitate protein capture and polishing and also in the filtration process for the removal of viruses or depyrogenation. Aqueous solutions are also required for cleaning and disinfecting downstream processing equipment, such as chromatography matrices and membrane filtration systems. The main equipment involved in downstream processing with buffers includes mixers for buffer preparation, as well as equipment for purification, including packed-bed chromatography systems, fluidized beds, ultrafiltration and diafiltration membranes, microfiltration membranes, depth filtration cartridges, and virus-removal systems.
The global Bio Pharma Buffer market was valued at US$ 841.4 million in 2023 and is anticipated to reach US$ 1376.7 million by 2030, witnessing a CAGR of 7.2% during the forecast period 2024-2030.
The key players are Avantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE, Healthcare, Promega Corporation, Hamilton Company, XZL BIO-TECHNOLOGY, SRL and so on. According to the revenue of these companies, we can know that the Bio Pharma Buffer industry is relative concentrated. Because the top 6 companies have more than 70% market share.
This report aims to provide a comprehensive presentation of the global market for Bio Pharma Buffer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bio Pharma Buffer.
Report Scope
The Bio Pharma Buffer market size, estimations, and forecasts are provided in terms of sales volume (K Liter) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bio Pharma Buffer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bio Pharma Buffer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Avantor
Alfa Aesar (Thermo Fisher)
Merck
Lonza
Bio-Rad
BD
GE Healthcare
Promega Corporation
Hamilton Company
XZL BIO-TECHNOLOGY
SRL
Segment by Type
Phosphates Type
Acetates Type
TRIS Type
Others
Segment by Application
Research Institution
Pharmaceutical Industry
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bio Pharma Buffer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bio Pharma Buffer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Most purification steps for downstream processing of biologics require buffers to equilibrate, condition, wash, elute, or concentrate the product. They are used in product isolation and purification steps to facilitate protein capture and polishing and also in the filtration process for the removal of viruses or depyrogenation. Aqueous solutions are also required for cleaning and disinfecting downstream processing equipment, such as chromatography matrices and membrane filtration systems. The main equipment involved in downstream processing with buffers includes mixers for buffer preparation, as well as equipment for purification, including packed-bed chromatography systems, fluidized beds, ultrafiltration and diafiltration membranes, microfiltration membranes, depth filtration cartridges, and virus-removal systems.
The global Bio Pharma Buffer market was valued at US$ 841.4 million in 2023 and is anticipated to reach US$ 1376.7 million by 2030, witnessing a CAGR of 7.2% during the forecast period 2024-2030.
The key players are Avantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE, Healthcare, Promega Corporation, Hamilton Company, XZL BIO-TECHNOLOGY, SRL and so on. According to the revenue of these companies, we can know that the Bio Pharma Buffer industry is relative concentrated. Because the top 6 companies have more than 70% market share.
This report aims to provide a comprehensive presentation of the global market for Bio Pharma Buffer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bio Pharma Buffer.
Report Scope
The Bio Pharma Buffer market size, estimations, and forecasts are provided in terms of sales volume (K Liter) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bio Pharma Buffer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bio Pharma Buffer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Avantor
Alfa Aesar (Thermo Fisher)
Merck
Lonza
Bio-Rad
BD
GE Healthcare
Promega Corporation
Hamilton Company
XZL BIO-TECHNOLOGY
SRL
Segment by Type
Phosphates Type
Acetates Type
TRIS Type
Others
Segment by Application
Research Institution
Pharmaceutical Industry
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bio Pharma Buffer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bio Pharma Buffer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Bio Pharma Buffer Market Overview
1.1 Product Overview and Scope of Bio Pharma Buffer
1.2 Bio Pharma Buffer Segment by Type
1.2.1 Global Bio Pharma Buffer Market Value Comparison by Type (2024-2030)
1.2.2 Phosphates Type
1.2.3 Acetates Type
1.2.4 TRIS Type
1.2.5 Others
1.3 Bio Pharma Buffer Segment by Application
1.3.1 Global Bio Pharma Buffer Market Value by Application: (2024-2030)
1.3.2 Research Institution
1.3.3 Pharmaceutical Industry
1.3.4 Others
1.4 Global Bio Pharma Buffer Market Size Estimates and Forecasts
1.4.1 Global Bio Pharma Buffer Revenue 2019-2030
1.4.2 Global Bio Pharma Buffer Sales 2019-2030
1.4.3 Global Bio Pharma Buffer Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bio Pharma Buffer Market Competition by Manufacturers
2.1 Global Bio Pharma Buffer Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bio Pharma Buffer Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bio Pharma Buffer Average Price by Manufacturers (2019-2024)
2.4 Global Bio Pharma Buffer Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bio Pharma Buffer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bio Pharma Buffer, Product Type & Application
2.7 Bio Pharma Buffer Market Competitive Situation and Trends
2.7.1 Bio Pharma Buffer Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bio Pharma Buffer Players Market Share by Revenue
2.7.3 Global Bio Pharma Buffer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bio Pharma Buffer Retrospective Market Scenario by Region
3.1 Global Bio Pharma Buffer Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bio Pharma Buffer Global Bio Pharma Buffer Sales by Region: 2019-2030
3.2.1 Global Bio Pharma Buffer Sales by Region: 2019-2024
3.2.2 Global Bio Pharma Buffer Sales by Region: 2025-2030
3.3 Global Bio Pharma Buffer Global Bio Pharma Buffer Revenue by Region: 2019-2030
3.3.1 Global Bio Pharma Buffer Revenue by Region: 2019-2024
3.3.2 Global Bio Pharma Buffer Revenue by Region: 2025-2030
3.4 North America Bio Pharma Buffer Market Facts & Figures by Country
3.4.1 North America Bio Pharma Buffer Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bio Pharma Buffer Sales by Country (2019-2030)
3.4.3 North America Bio Pharma Buffer Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Bio Pharma Buffer Market Facts & Figures by Country
3.5.1 Europe Bio Pharma Buffer Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bio Pharma Buffer Sales by Country (2019-2030)
3.5.3 Europe Bio Pharma Buffer Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bio Pharma Buffer Market Facts & Figures by Country
3.6.1 Asia Pacific Bio Pharma Buffer Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bio Pharma Buffer Sales by Country (2019-2030)
3.6.3 Asia Pacific Bio Pharma Buffer Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Bio Pharma Buffer Market Facts & Figures by Country
3.7.1 Latin America Bio Pharma Buffer Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bio Pharma Buffer Sales by Country (2019-2030)
3.7.3 Latin America Bio Pharma Buffer Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bio Pharma Buffer Market Facts & Figures by Country
3.8.1 Middle East and Africa Bio Pharma Buffer Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bio Pharma Buffer Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bio Pharma Buffer Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Bio Pharma Buffer Sales by Type (2019-2030)
4.1.1 Global Bio Pharma Buffer Sales by Type (2019-2024)
4.1.2 Global Bio Pharma Buffer Sales by Type (2025-2030)
4.1.3 Global Bio Pharma Buffer Sales Market Share by Type (2019-2030)
4.2 Global Bio Pharma Buffer Revenue by Type (2019-2030)
4.2.1 Global Bio Pharma Buffer Revenue by Type (2019-2024)
4.2.2 Global Bio Pharma Buffer Revenue by Type (2025-2030)
4.2.3 Global Bio Pharma Buffer Revenue Market Share by Type (2019-2030)
4.3 Global Bio Pharma Buffer Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bio Pharma Buffer Sales by Application (2019-2030)
5.1.1 Global Bio Pharma Buffer Sales by Application (2019-2024)
5.1.2 Global Bio Pharma Buffer Sales by Application (2025-2030)
5.1.3 Global Bio Pharma Buffer Sales Market Share by Application (2019-2030)
5.2 Global Bio Pharma Buffer Revenue by Application (2019-2030)
5.2.1 Global Bio Pharma Buffer Revenue by Application (2019-2024)
5.2.2 Global Bio Pharma Buffer Revenue by Application (2025-2030)
5.2.3 Global Bio Pharma Buffer Revenue Market Share by Application (2019-2030)
5.3 Global Bio Pharma Buffer Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Avantor
6.1.1 Avantor Corporation Information
6.1.2 Avantor Description and Business Overview
6.1.3 Avantor Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Avantor Bio Pharma Buffer Product Portfolio
6.1.5 Avantor Recent Developments/Updates
6.2 Alfa Aesar (Thermo Fisher)
6.2.1 Alfa Aesar (Thermo Fisher) Corporation Information
6.2.2 Alfa Aesar (Thermo Fisher) Description and Business Overview
6.2.3 Alfa Aesar (Thermo Fisher) Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Alfa Aesar (Thermo Fisher) Bio Pharma Buffer Product Portfolio
6.2.5 Alfa Aesar (Thermo Fisher) Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Bio Pharma Buffer Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Lonza
6.4.1 Lonza Corporation Information
6.4.2 Lonza Description and Business Overview
6.4.3 Lonza Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Lonza Bio Pharma Buffer Product Portfolio
6.4.5 Lonza Recent Developments/Updates
6.5 Bio-Rad
6.5.1 Bio-Rad Corporation Information
6.5.2 Bio-Rad Description and Business Overview
6.5.3 Bio-Rad Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bio-Rad Bio Pharma Buffer Product Portfolio
6.5.5 Bio-Rad Recent Developments/Updates
6.6 BD
6.6.1 BD Corporation Information
6.6.2 BD Description and Business Overview
6.6.3 BD Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.6.4 BD Bio Pharma Buffer Product Portfolio
6.6.5 BD Recent Developments/Updates
6.7 GE Healthcare
6.6.1 GE Healthcare Corporation Information
6.6.2 GE Healthcare Description and Business Overview
6.6.3 GE Healthcare Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GE Healthcare Bio Pharma Buffer Product Portfolio
6.7.5 GE Healthcare Recent Developments/Updates
6.8 Promega Corporation
6.8.1 Promega Corporation Corporation Information
6.8.2 Promega Corporation Description and Business Overview
6.8.3 Promega Corporation Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Promega Corporation Bio Pharma Buffer Product Portfolio
6.8.5 Promega Corporation Recent Developments/Updates
6.9 Hamilton Company
6.9.1 Hamilton Company Corporation Information
6.9.2 Hamilton Company Description and Business Overview
6.9.3 Hamilton Company Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hamilton Company Bio Pharma Buffer Product Portfolio
6.9.5 Hamilton Company Recent Developments/Updates
6.10 XZL BIO-TECHNOLOGY
6.10.1 XZL BIO-TECHNOLOGY Corporation Information
6.10.2 XZL BIO-TECHNOLOGY Description and Business Overview
6.10.3 XZL BIO-TECHNOLOGY Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.10.4 XZL BIO-TECHNOLOGY Bio Pharma Buffer Product Portfolio
6.10.5 XZL BIO-TECHNOLOGY Recent Developments/Updates
6.11 SRL
6.11.1 SRL Corporation Information
6.11.2 SRL Bio Pharma Buffer Description and Business Overview
6.11.3 SRL Bio Pharma Buffer Sales, Revenue and Gross Margin (2019-2024)
6.11.4 SRL Bio Pharma Buffer Product Portfolio
6.11.5 SRL Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bio Pharma Buffer Industry Chain Analysis
7.2 Bio Pharma Buffer Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bio Pharma Buffer Production Mode & Process
7.4 Bio Pharma Buffer Sales and Marketing
7.4.1 Bio Pharma Buffer Sales Channels
7.4.2 Bio Pharma Buffer Distributors
7.5 Bio Pharma Buffer Customers
8 Bio Pharma Buffer Market Dynamics
8.1 Bio Pharma Buffer Industry Trends
8.2 Bio Pharma Buffer Market Drivers
8.3 Bio Pharma Buffer Market Challenges
8.4 Bio Pharma Buffer Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
